Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin by Meczes, E L et al.
Schedule-dependent response of neuroblastoma cell lines to
combinations of etoposide and cisplatin
EL Meczes
1, ADJ Pearson
2, CA Austin
3 and MJ Tilby*
,1
1Paediatric Oncology Laboratory, Cancer Research Unit, Catherine Cookson Building, The Medical School, The University of Newcastle upon Tyne, Newcastle
upon Tyne NE2 4HH UK;
2Department of Child Health, Sir James Spence Inst. Royal Victoria Inﬁrmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP,
UK;
3Department of Biochemistry and Genetics, The Medical School, The University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
The growth inhibitory effects of cisplatin and etoposide on neuroblastoma cell lines were investigated in several scheduled
combinations. Results were analyzed using median effect and combination index analyses. In all schedules in which cisplatin was
administered prior to etoposide a synergistic effect was observed. Conversely, an antagonistic effect was seen in all schedules
where etoposide was administered before cisplatin.
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The design of the widely used OPEC protocol (oncovins, platinum
agents, epipodophyllotoxins and cyclophosphamide) for manage-
ment of the paediatric solid tumour neuroblastoma was based on
clinical and in vitro evaluations of sequentially scheduled cisplatin
and the epipodophyllotoxin, teniposide. These studies indicated
that, for optimal anti-tumour effect, cisplatin should be adminis-
tered prior to the epipodophyllotoxin (Hayes et al, 1981;
Shafford et al, 1984; Pritchard et al, 1985).
In several more recent clinical protocols for neuroblastoma, this
apparently optimal order of drug administration has not been
retained. The order of administration has been reversed in some
regimens (Gordon et al, 1992; Tweddle et al, 2001) or the drugs
are administered concurrently (reviewed in Pinkerton et al,
2000). If the OPEC rationale was correct, this altered scheduling
pattern could result in sub-optimal response. Furthermore, in
many of these schedules, cisplatin has been replaced by carboplatin.
This will accentuate the change in order of administration because,
despite the fact that carboplatin forms essentially the same ﬁnal
DNA adducts as cisplatin, the cytotoxic cross-linked structures
develop more slowly than with cisplatin (Knox et al, 1986).
The present study was aimed at determining, using contemp-
orary methods of analysis, whether the currently used epipodophyl-
lotoxin, etoposide, in combination with cisplatin, caused effects on
neuroblastoma cell lines that were dependent upon the relative
timings of the drug exposures.
MATERIALS AND METHODS
Cell culture and drug solutions
The neuroblastoma cell lines SHSY5Y (Ciccarone et al, 1989) and
NGP (Brodeur et al, 1977) were kindly provided by Drs P Lovat
and D Tweddle (University of Newcastle upon Tyne). Cells were
grown in RPMI 1640 (Dutch modiﬁcation, supplemented with
10% v/v foetal bovine serum, and antibiotics (Gibco BRL)) at
378C/5% CO2. Frequent tests for mycoplasma infection were
always negative. Etoposide was dissolved in methanol and stored
at 7208C. Cisplatin was freshly dissolved in DMSO just prior to
each experiment and immediately diluted into medium. During
drug exposures, the concentrations of methanol and DMSO were
kept below 1% and 0.001% respectively in treated and control
wells.
Sulphorhodamine B (SRB) assay
For each experiment, cells were inoculated into three 96-well
tissue culture plates and incubated for 24 h prior to starting drug
exposures (time zero). Plates were exposed to graded concentra-
tions of either: the ﬁrst drug in the schedule only followed by
the diluent for the second drug; the diluent for the ﬁrst drug
in the schedule followed by the second drug in the schedule; or
both drugs in the schedule according to the schedule design.
The plates were washed twice in drug free medium in between
each drug/diluent exposure. After the ﬁnal wash plates were
returned to the incubator for 5 days. Procedures for ﬁxing, stain-
ing and reading (OD570) were carried out as described by Skehan
et al (1990).
Median effect and combination index analysis
Drug interactions were analyzed using CalcuSyn (Chou and
Hayball, 1996). This software calculates the median effect dose,
Dm (analogous to the IC50), of the drug combinations using
the median effect equation. Determination of synergy or antag-
onism was based on the multiple drug effect equation of Chou
and Talalay (1977, 1983) and was quantiﬁed by the combina-
tion index (CI). CI=1 indicates an additive effect; 51,
synergy, 41, antagonism. Results are shown for the mutually
exclusive assumption of modes of activity of the drugs,
however, applying the alternative assumption showed the same
pattern of results.
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Response of neuroblastoma cell lines to single agents
A prerequisite for evaluating the effect of drug combinations on
cells is the determination of the effects of each agent acting alone
within the schedule, retaining the exact timings of drug exposure as
in the combined treatments. Effects of single agents were measured
under four different schedules, which paralleled the more complex
conditions of the combination experiments.
The responses of SHSY5Y cells exposed to etoposide were
affected by the interval between seeding and drug exposure as is
illustrated by the Dm values in Table 1. Sensitivity of the cells
exposed to etoposide for 4 or 24 h periods, decreased with an
increase in the interval between seeding and drug exposure.
Sensitivity of NGP cells to etoposide was not dependent on the
time interval between seeding and drug exposure and was approxi-
mately 5–10-fold greater than the SHSY5Y cells (Table 1).
The responses of SHSY5Y and NGP cells to cisplatin, were inde-
pendent of the time interval between seeding and drug exposure
(Table 1). NGP cells were slightly more sensitive to cisplatin than
SHSY5Y cells (Table 1).
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Table 1 Median effect (Dm) concentrations of single agent cisplatin or
etoposide for SHSY5Y cells and NGP cells exposed for the time intervals
and schedules speciﬁed
Schedule Exposure Dm (m mmol l mol l
7 71 1) )
(+24 h after length +s.d. (medium
Cell line Drug seeding) (h) effect dose)
SHSY5Y Etoposide 0–4 (B and G) 4 2.47+0.45
24–28 (A) 4 5.57+1.57
48–52 (F) 4 9.61+1.51
0–24 (E and D) 24 0.49+0.11
24–48 (C) 24 0.91+0.21
Cisplatin 0–24 (A, C, D and F) 24 0.96+0.10
4–28 (B) 24 1.00+0.15
24–48 (E) 24 1.07+0.22
28–52 (G) 24 1.07+0.23
NGP Etoposide 0–24 (E) 24 0.10+0.03
24–48 (C) 24 0.12+0.02
Cisplatin 0–24 (C) 24 0.60+0.04
24–48 (E) 24 0.67+0.11
Each value is the mean of at least three experiments. The letters in brackets indicate
the corresponding combination schedules described in Table 2 and Figures 1–3.
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Figure 1 Dose response curves for SHSY5Y cells exposed to scheduled exposures of cisplatin and etoposide. For each schedule, curves are shown for
both drugs as single agents administered at appropriate time points together with the drug combination. Cells were seeded in 96-well plates and allowed to
adhere for 24 h (time 0). Cells were exposed to either a mixture of cisplatin and etoposide for 24 h (D), or, cisplatin for 24 h (A, C, F), washed and further
exposed to 4 h of etoposide (A), 24 h etoposide (C) or drug free medium for 24 h followed by 4 h of etoposide (F). Panels B, E and G show the reverse of
schedules shown in A, C, and F respectively. The mean of at least three experiments are shown and error bars represent standard deviations (s.d.) from the
mean. For schematics at the top of each panel, black rectangles represent cisplatin exposures, white rectangles represent etoposide exposures.
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and cisplatin
Figure 1 shows the dose response curves for SHSY5Y cells in each
of seven schedules and Figure 2 shows the mean combination
index (CI) values plotted against fraction of cells affected. Figure
1C, D and E represent the results obtained when each drug was
present for 24 h, either one immediately before the other or
concurrently. There was little difference between the dose-response
curves or Dm values for these schedules (Figure 1 and Table 2).
However, the Dm values alone do not take into account the effect
of the timing upon etoposide sensitivity in relation to seeding of
the cells. As reported above, cells exposed to etoposide at time zero
were approximately two-fold more sensitive than cells exposed 24 h
later (Table 1). Combination index analysis based on single drug
controls, takes this effect into account (Figure 2 and Table 2).
Comparison of C, D and E in Figure 2 show a trend for the CI
values to increase as the order of drug exposure changes from
cisplatin ﬁrst, to simultaneous exposure, to cisplatin last. For sche-
dule C, most CI values were less than one, indicating a slight
degree of synergy, while for schedule E, most values were greater
than one, indicating antagonism.
In experiments aimed at more closely representing the clinical
schedules of OPEC and OJEC, cisplatin exposure was for 24 h
while etoposide was added for 4 h. When the drug exposures
followed each other immediately, combination index values were
slightly lower when cisplatin preceded etoposide (Figure 2A,B).
When a 24 h period occurred between the same drug exposures,
cisplatin before etoposide (schedule F), resulted in a lower degree
of inhibition and higher Dm values (Table 2) compared to the
opposite order (Figure 1F,G). This was the predicted result based
on the difference in potency between etoposide administered at
zero time and at 48 h after zero time (approximately four-fold;
Table 1). However, the CI values were consistently less than 1 when
exposure to cisplatin was ﬁrst (Figure 2F,G), indicating that the
synergistic effect of this drug sequence was enough to overcome
the increased potency of etoposide when it was added at zero time.
Overall, the data in Figure 2 show that, changing schedules from
cisplatin ﬁrst (left-hand panels) to cisplatin last (right-hand panels)
resulted in increased CI values. This indicates a consistent change
from synergy to antagonism when the etoposide exposure was
changed from after to before cisplatin.
Response of NGP cells to combinations of etoposide and
cisplatin
For NGP cells, the schedule in which cisplatin was administered for
24 h prior to etoposide for 24 h required signiﬁcantly lower doses
to achieve 50% inhibition of growth than did the reverse schedule
(Table 2).
The combination index analyses conﬁrmed the difference
between the Dm values for these schedules (Figure 3). For schedule
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Figure 2 Combination index plots for SHSY5Y cells exposed to scheduled exposures of cisplatin and etoposide. Combination index plots were gener-
ated by the computer software CalcuSyn
1 for each of at least three experiments for each schedule. The data points in each panel represent the means of
the generated plots and error bars represent the standard deviations. The equation for calculation of the combination index for two drugs (1 and 2) with
mutually exclusive modes of action at the median effect dose is also shown. For schematics at the top of each panel, black rectangles represent cisplatin
exposures, white rectangles represent etoposide exposures.
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majority of the CI values were less than 1, indicating synergy
(Figure 3A). Conversely, for schedule E, the majority of the values
were greater than 1, indicating antagonism (Figure 3B). Therefore,
cisplatin prior to etoposide produced the greatest growth inhibitory
effect upon NGP cells.
DISCUSSION
Scheduling patterns in which cells were exposed to both drugs,
each for 24 h were shown to result in a synergistic response in both
SHSY5Y cells and NGP cells when cisplatin was administered prior
to etoposide. SHSY5Y cells also exhibited this response when the
exposure time to etoposide was reduced to 4 h (NGP cells were
not tested with this schedule). Introducing a 24 h drug-free period
between drug exposures gave a similar pattern of combination
indexes to the other schedules. Overall, the results showed that
changing schedules from cisplatin ﬁrst to cisplatin last resulted in
a change from synergy to antagonism. The exact degrees of
synergy/antagonism are probably dependent upon both the model
underlying the analysis method and the techniques used to measure
cytotoxicity.
In the recently developed OJEC protocol for neuroblastoma
therapy, carboplatin is administered for 1 h immediately follow-
ing a 4 h etoposide infusion (Tweddle et al, 2001), allowing
day-care chemotherapy. This is a reversal of the OPEC protocol
in which cisplatin is infused for 24 h, followed by 24 h post-
hydration and ﬁnally 4 h of etoposide. Replacement of cisplatin
by carboplatin also reduces toxic side-effects. Cisplatin and
carboplatin form essentially the same DNA-adduct structures
(Knox et al, 1986), however, carboplatin monofunctional adducts
are converted to bifunctional adducts much more slowly than
those formed with cisplatin (Knox et al, 1986; Peng et al,
1997), further complicating analysis of synergy. This slow forma-
tion of the toxic products with carboplatin will tend to enhance
the antagonistic effects of administration of the platinum agent
after etoposide.
Etoposide acts via the stabilization of topoisomerase II (topo II)
cleavable complexes. This effect is reversible and furthermore
etoposide has a short elimination half-life (Hsiang and Liu, 1989;
Slevin, 1991; Caldecott et al, 1993; Willmore et al, 1998). Together
with the slow formation of carboplatin-DNA adducts, the swift
reversal of etoposide stabilised topo II cleavable complexes may
result in reduced anti-tumour effect in patients.
In conclusion, if the results of this study are reﬂected by the
action of drugs in the patient, then the adoption of schedules
in which platinum agent follows etoposide and in which forma-
tion of platinum-DNA cross-links is delayed (carboplatin as
opposed to cisplatin) may result in sub-optimal anticancer
action. An understanding of the underlying mechanisms of
interaction may help assessment of the clinical relevance of
these effects.
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Figure 3 Combination index plots for NGP cells exposed to scheduled exposures of etoposide and cisplatin. The computer software CalcuSyn
1 simu-
lates combination index curves to ﬁt experimental values. For each schedule, the mean and standard errors are shown for at least three replicate experi-
ments. The dotted line at CI=1 represents additivity. Values above this line indicate antagonism, below this line indicates synergy. (A) Sequential exposure to
cisplatin followed by etoposide each for 24 h (Schedule C). (B) the reverse of A. (Schedule E).
Table 2 Median effect (Dm) concentrations and combination index (CI) values for SHSY5Y and NGP cells exposed to scheduled/concur-
rent combinations of cisplatin and etoposide
Ratio
DM (mmol l
71)+s.d.
Cell line Schedule Details (etoposide:cisplatin) Etoposide Cisplatin CI50+s.d.
SHSY5Y A Cisplatin 0–24, etoposide 24–28 1:4 1.95+0.33 0.49+0.08 0.84+0.03
B Etoposide 0–4, cisplatin 4–28 1:4 1.69+0.09 0.42+0.02 1.04+0.15
C Cisplatin 0–24, etoposide 24–48 1:1 0.38+0.04 0.38+0.04 0.89+0.12
D Concurrent exposure (24 h) 1:4 0.38+0.02 0.38+0.02 1.09+0.24
E Etoposide 0–24, cisplatin 24–48 1:4 0.40+0.07 0.40+0.07 1.20+0.03
F Cisplatin 0–24, gap 24–48, etoposide 48–52 1:4 2.33+0.19 0.58+0.05 0.82+0.10
G Etoposide 0–4, gap 4–28, cisplatin 28–52 1:4 1.40+0.32 0.35+0.08 1.00+0.28
NGP C Cisplatin 0–24, etoposide 24–48 10:1 0.026+0.002 0.26+0.02 0.66+0.03
E Etoposide 0–24, cisplatin 24–48 10:1 0.046+0.014 0.46+0.14 1.07+0.22
Cells were exposed to the drugs at their equipotent ratios (as recommended by Chou and Hayball, 1996) using the ratios of Dm values determined for the
appropriate exposure timings (Table 1). Each value is the mean of at least three experiments.
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